WHAT IS CLAIMED IS:

1. A compound of structural formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein;

R^1 is selected from:

(1) C_{1-10}alkyl,

(2) C_{3-10}cycloalkyl,

(3) cycloheteroalkyl,

(4) aryl, and

(5) heteroaryl,

wherein alky is optionally substituted with one, two, three or four substituents independently selected from R^a, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R^2 is selected from:

(1) C_{3-10}cycloalkyl,

(2) cycloheteroalkyl,

(3) aryl,

(4) heteroaryl,

(5) $-OR^d$,

(6) $-NR^cR^d$, and

(7) $-CO_2R^d$,

wherein each alkyl is optionally substituted with one , two, three or four substituents independently selected from R^a, and each cycloalkyl, and cycloheteroalkyl aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R^3 is selected from:

(1) C_{1-4}alkyl,

(2) C_{2-4}alkenyl,
(3) C_{2-4}alkynyl,
(4) C_{3-7}cycloalkyl,
wherein alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted with one, two, three or four substituents independently selected from R^a;

R^4 is selected from:
(1) hydrogen,
(2) C_{1-4}alkyl,
(3) C_{2-4}alkenyl,
(4) C_{2-4}alkynyl,
(5) $-OR^c$,
(6) $-CO_2R^c$
(7) $-OCOR^c$
(8) $-OCOOR^c$
(9) $-OCONR^dR^e$
(10) $-NR^dR^e$,
(11) $-NH(CO)OR^c$,
(12) $-NR^cSO_2R^c$
(13) $-S(O)mR^c$
(14) aryl,
(15) heteroaryl,
wherein alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl are optionally substituted with one, two, three or four substituents independently selected from R^a, and aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R^6 is selected from:
(1) hydrogen,
(2) C_{1-4}alkyl,
(3) C_{2-4}alkenyl,
(4) C_{2-4}alkynyl,
(5) $-OR^d$,
(6) halogen,
(7) -CN,
(8) $-NR^cR^d$,

wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from R^a

A is a 3- to 8-membered monocyclic saturated ring incorporating the same carbon atom to which R^4 is attached and optionally containing one to two heteroatoms chosen from oxygen, nitrogen, and sulfur, and to which an aryl or heteroaryl ring is fused, wherein said bicyclic ring is optionally fused to another aryl or heteroaryl ring to form a tricyclic ring wherein the A ring system is optionally substituted with one, two, three or four substituents selected from a group independently selected from oxo and R^b;

each R^a is independently selected from:

(1) $-OR^d$,
(2) $-NR^cS(O)_mR^d$,
(3) $-NO_2$,
(4) halogen,
(5) $-S(O)_mR^c$,
(6) $-SR^c$,
(7) $-S(O)_2OR^c$,
(8) $-S(O)_mNR^cR^d$,
(9) $-NR^cR^d$,
(10) $-O(CR^eR^f)_nNR^cR^d$,
(11) $-C(O)R^c$,
(12) $-CO_2R^c$,
(13) $-CO_2(CR^eR^f)_nCONR^cR^d$,
(14) $-OC(O)R^c$,
(15) -CN,
(16) $-C(O)NR^cR^d$,
(17) $-NR^cC(O)R^d$,
(18) $-OC(O)NR^cR^d$,
(19) $-NR^cC(O)OR^d$,
(20) $-NR^cC(O)NR^cR^d$,
(21) $-CR^c(N\text{-}OR^d)$,
(22) CF_3,
(23) $-OCF_3$,
(24) C_{3-8}cycloalkyl, and
(25) cycloheteroalkyl;

each R^b is independently selected from:

(1) R^a,
(2) C_{1-10}alkyl,
(3) aryl,
(4) arylC_{1-4}alkyl,
(5) heteroaryl, and
(6) heteroarylC_{1-4}alkyl;

R^c and R^d are independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) C_{2-10} alkenyl,
(4) C_{2-10}alkynyl,
(5) cycloalkyl,
(6) cycloalkyl-C_{1-10}alkyl;
(7) cycloheteroalkyl,
(8) cycloheteroalkyl-C_{1-10} alkyl;
(9) aryl,
(10) heteroaryl,
(11) aryl-C_{1-10}alkyl, and
(12) heteroaryl-C_{1-10}alkyl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

each R^c and R^d may be unsubstituted or substituted on a carbon or nitrogen atom with one, two or three substituents selected from R^h;

R^e and R^f are independently selected from hydrogen, C_{1-10}alkyl, C_{2-10} alkenyl, C_{2-10}alkynyl, cycloalkyl, cycloalkyl-C_{1-10} alkyl, cycloheteroalkyl, cycloheteroalkyl-C_{1-10} alkyl, aryl, heteroaryl, aryl-C_{1-10} alkyl, and heteroaryl-C_{1-10} alkyl; or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each Rg is independently selected from

(1) hydrogen,
(2) C_{1-10}alkyl,

(3) C_{3-8}cycloalkyl,
(4) heterocycloalkyl,
(5) aryl,
(6) arylC_{1-4}alkyl,
(7) heteroaryl,
(8) heteroarylC_{1-4}alkyl,
(9) $-S(O)_mR^c$,
(10) $-C(O)R^c$,
(11) $-CO_2R^c$,
(12) $-CO_2(CR^eR^f)_nCONR^cR^d$, and
(13) $-C(O)NR^cR^d$;

each R^h is independently selected from:
(1) halogen,
(2) C_{1-10}alkyl,
(3) C_{3-8}cycloalkyl,
(4) heterocycloalkyl,
(5) aryl,
(6) arylC_{1-4}alkyl,
(7) heteroaryl,
(8) heteroarylC_{1-4}alkyl,
(9) $-OR^c$,
(10) $-NR^cS(O)_mR^d$,
(11) $-S(O)_mR^c$,
(12) $-SR^c$,
(13) $-S(O)_2OR^c$,
(14) $-S(O)_mNR^cR^d$,
(15) $-NR^cR^d$,
(16) $-O(CR^eR^f)_nNR^cR^d$,
(17) $-C(O)R^c$,
(18) $-CO_2R^c$,
(19) $-CO_2(CR^eR^f)_nCONR^cR^d$,
(20) $-OC(O)R^c$,
(21) -CN,
(22) $-C(O)NR^cR^d$,

(23) -$NR^cC(O)R^d$,
(24) -$OC(O)NR^cR^d$,
(25) -$NR^cC(O)OR^d$,
(26) -$NR^cC(O)NR^cR^d$,
(27) CF_3, and
(28) -OCF_3,

m is selected from 1 and 2; and

n is selected from 1, 2, and 3;

or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1, wherein R^4 is selected from:

(1) hydrogen,
(2) C_{1-4}alkyl, and
(3) cyclopropyl,

wherein alkyl and cyclopropyl are optionally substituted with one, two or three R^a substituents;

and pharmaceutically acceptable salts thereof.

3. The compound according to Claim 2, wherein R^3 is selected from:

(1) methyl,
(2) trifluoromethyl, and
(3) cyclopropyl;

and pharmaceutically acceptable salts thereof.

4. The compound according to Claim 3, R^1 is selected from:

(1) C_{1-4}alkyl,
(2) C_{3-10}cycloalkyl-,
(3) cycloheteroalkyl,
(4) phenyl, and
(5) pyridyl,

wherein each alkyl is optionally substituted with one R^a substituent, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one to three substituents independently selected from R^b;

and pharmaceutically acceptable salts thereof.

5. The compound according to Claim 4, wherein R^2 is selected from:

R^2 is selected from:

(1) C_{1-10}alkyl,

(2) C_{3-10}cycloalkyl,

(3) cycloheteroalkyl,

(4) aryl,

(5) heteroaryl,

(6) $-OR^d$,

(7) $-NR^cR^d$, and

(8) $-CO_2R^d$, and

wherein each alkyl is optionally substituted with one, two or three substituents independently selected from R^a, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one, two or three substitutents independently selected from R^b;

and pharmaceutically acceptable salts thereof.

6. The compound according to Claim 5, wherein **A** is a cyclopentyl, cyclohexyl, cycloheptyl, dioxanyl, tetrahydrofuranyl, or oxanyl, ring fused to a phenyl, or pyrrolyl ring, optionally fused to a phenyl ring to form a tricyclic ring wherein the **A** ring system is optionally substituted with one, two or three R^b substituents;

and pharmaceutically acceptable salts thereof.

7. The compound according to Claim 1, wherein:

R^1 is selected from:

(1) isopropyl,

(2) isobutyl,

(3) n-propyl,

(4) cyclopropyl,
(5) cyclobutyl,
(6) cyclopentyl,
(7) cyclohexyl,
(8) piperidinyl,
(9) phenyl, and
(10) pyridyl,

wherein each alkyl is optionally substituted with one R^a substituent, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one to three substituents independently selected from R^b;

R^2 is selected from:

(1) cyclobutyl,
(2) cyclopentyl,
(3) cyclohexyl,
(4) pyrrolidinyl,
(5) pyrimidinyl,
(6) benzoxazolyl,
(7) dihydroindolyl,
(8) dihydroquinolinyl,
(9) benzotriazolyl,
(10) thiophenyl,
(11) indolyl,
(12) indazolyl,
(13) pyrrolidinyl,
(14) pyridazinyl
(15) triazolyl,
(16) azaindolyl,
(17) cyclobutylmethoxy,
(18) phenyl,
(19) pyridyl,
(20) $-NR^cR^d$, and
(21) $-CO_2R^d$,

wherein each alkyl is optionally substituted with one or two R^a substituents and each phenyl or pyridyl is independently with one to three R^b substituents.

R^3 is methyl;

R^4 is selected from hydrogen and methyl;

R^6 is selected from:

(1) hydrogen,
(2) methyl,
(3) hydroxyl,
(4) halogen, and
(5) –CN;

A is selected from:

(1) benzodioxanyl,
(2) indanyl,
(3) 1,2,3,4-tetrahydronaphthyl,
(4) 6,7,8,9-tetrahydro[a][7]annulenyl,
(5) chromanyl,
(6) 2,3-dihydrobenzyl furanyl,
(7) 1,2,3,4-tetrahydroquinolinyl,
(8) 1,2,3,4-tetrahydroisoquinolinyl,
(9) 1,2,3,4-tetrahydro-1,4-quinazolinyl, and
(10) 1,2,3,4-tetrahydrocarbolinyl,

each optionally substituted with one, two, or three groups independently selected from R^b;

each R^b is independently selected from:

(1) methoxy,
(2) halogen,
(3) -SH,
(4) $-SCH_3$,
(5) $-NH_2$,
(6) $-C(O)CH_3$,
(7) $-CO_2H$,
(8) $-CO_2CH_3$,
(9) $-CF_3$,
(10) $-OCF_3$,
(11) C_{3-6} cycloalkyl,
(12) C_{1-4}alkyl,
(13) phenyl,

(14) benzyl, and

(15) heteroaryl;

and pharmaceutically acceptable salts thereof.

8. A compound of structural formula IA:



(IA)

or a pharmaceutically acceptable salt thereof, wherein;

R^1 is selected from:

(1) aryl,

(2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R^2 is selected from:

(1) aryl,

(2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R^3 is selected from:

(1) C_{1-4}alkyl,

(2) C_{2-4}alkenyl,

(3) C_{2-4}alkynyl,

(4) C_{3-7}cycloalkyl,

wherein alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted with one, two, three or four substituents independently selected from R^a;

R^4 is selected from:

(1) hydrogen,

(2) C_{1-4}alkyl,

(3) C_{2-4}alkenyl,

(4) C_{2-4}alkynyl,

(5) –OR^c,
(6) -CO_2R^c
(7) –$OCOR^c$
(8) –$OCOOR^c$
(9) –$OCONR^dR^e$
(10) –NR^dR^e,
(11) –$NH(CO)OR^c$,
(12) –$NR^cSO_2R^c$
(13) –$S(O)mR^c$
(14) aryl,
(15) heteroaryl,

wherein alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl are optionally substituted with one, two, three or four substituents independently selected from R^a, and aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

A is a 3- to 8-membered monocyclic saturated ring incorporating the same carbon atom to which R^4 is attached and optionally containing one to two heteroatoms chosen from oxygen, nitrogen, and sulfur, and to which an aryl or heteroaryl ring is fused, wherein said bicyclic ring is optionally fused to another aryl or heteroaryl ring to form a tricyclic ring wherein the A ring system is optionally substituted with one, two, three or four substituents selected from a group independently selected from oxo and R^b;

each R^a is independently selected from:

(1) -OR^d,
(2) -$NR^cS(O)_mR^d$,
(3) -NO_2,
(4) halogen,
(5) -$S(O)_mR^c$,
(6) -SR^c,
(7) -$S(O)_2OR^c$,
(8) -$S(O)_mNR^cR^d$,
(9) -NR^cR^d,
(10) -$O(CR^eR^f)_nNR^cR^d$,
(11) -$C(O)R^c$,

(12) $-CO_2R^c$,
(13) $-CO_2(CR^eR^f)_nCONR^cR^d$,
(14) $-OC(O)R^c$,
(15) -CN,
(16) $-C(O)NR^cR^d$,
(17) $-NR^cC(O)R^d$,
(18) $-OC(O)NR^cR^d$,
(19) $-NR^cC(O)OR^d$,
(20) $-NR^cC(O)NR^cR^d$,
(21) $-CR^c(N-OR^d)$,
(22) CF_3,
(23) $-OCF_3$,
(24) C_{3-8}cycloalkyl, and
(25) cycloheteroalkyl;

each R^b is independently selected from:
(1) R^a,
(2) C_{1-10}alkyl,
(3) aryl,
(4) arylC_{1-4}alkyl,
(5) heteroaryl, and
(6) heteroarylC_{1-4}alkyl;

R^c and R^d are independently selected from:
(1) hydrogen,
(2) C_{1-10}alkyl,
(3) C_{2-10} alkenyl,
(4) C_{2-10}alkynyl,
(5) cycloalkyl,
(6) cycloalkyl-C_{1-10}alkyl;
(7) cycloheteroalkyl,
(8) cycloheteroalkyl-C_{1-10} alkyl;
(9) aryl,
(10) heteroaryl,
(11) aryl-C_{1-10}alkyl, and
(12) heteroaryl-C_{1-10}alkyl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and N-R^g,

each R^c and R^d may be unsubstituted or substituted on a carbon or nitrogen atom with one, two or three substituents selected from R^h;

R^e and R^f are independently selected from hydrogen, C_{1-10}alkyl, C_{2-10} alkenyl, C_{2-10}alkynyl, cycloalkyl, cycloalkyl-C_{1-10} alkyl, cycloheteroalkyl, cycloheteroalkyl-C_{1-10} alkyl, aryl, heteroaryl, aryl-C_{1-10} alkyl, and heteroaryl-C_{1-10} alkyl; or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each R^g is independently selected from

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) C_{3-8}cycloalkyl,
(4) heterocycloalkyl,
(5) aryl,
(6) arylC_{1-4}alkyl,
(7) heteroaryl,
(8) heteroarylC_{1-4}alkyl,
(9) $-S(O)_mR^c$,
(10) $-C(O)R^c$,
(11) $-CO_2R^c$,
(12) $-CO_2(CR^eR^f)_nCONR^cR^d$, and
(13) $-C(O)NR^cR^d$;

each R^h is independently selected from:

(1) halogen,
(2) C_{1-10}alkyl,
(3) C_{3-8}cycloalkyl,
(4) heterocycloalkyl,
(5) aryl,
(6) arylC_{1-4}alkyl,
(7) heteroaryl,
(8) heteroarylC_{1-4}alkyl,

(9) -OR^c,
(10) -$NR^cS(O)_mR^d$,
(11) -$S(O)_mR^c$,
(12) -SR^c,
(13) -$S(O)_2OR^c$,
(14) -$S(O)_mNR^cR^d$,
(15) -NR^cR^d,
(16) -$O(CR^eR^f)_nNR^cR^d$,
(17) -$C(O)R^c$,
(18) -CO_2R^c,
(19) -$CO_2(CR^eR^f)_nCONR^cR^d$,
(20) -$OC(O)R^c$,
(21) -CN,
(22) -$C(O)NR^cR^d$,
(23) -$NR^cC(O)R^d$,
(24) -$OC(O)NR^cR^d$,
(25) -$NR^cC(O)OR^d$,
(26) -$NR^cC(O)NR^cR^d$,
(27) CF_3, and
(28) -OCF_3,

m is selected from 1 and 2; and
n is selected from 1, 2, and 3;
or a pharmaceutically acceptable salt thereof.

9. The compound according to Claim 8, wherein R^4 is selected from:

(1) hydrogen,
(2) C_{1-4}alkyl, and
(3) cyclopropyl,

wherein alkyl and cyclopropyl are optionally substituted with one, two or three R^a substituents;

and pharmaceutically acceptable salts thereof.

10. The compound according to Claim 9, wherein R^3 is selected from:

(1) methyl,
(2) trifluoromethyl, and
(3) cyclopropyl;

and pharmaceutically acceptable salts thereof.

11. The compound according to Claim 10, wherein R^1 is selected from:

(1) phenyl, and
(2) pyridyl;

wherein phenyl and pyridyl are optionally substituted with one or two R^b substituents;

and pharmaceutically acceptable salts thereof.

12. The compound according to Claim 11, wherein R^2 is selected from:

(1) phenyl, and
(2) pyridyl;

wherein phenyl and pyridyl are optionally substituted with one or two R^b substituents.

and pharmaceutically acceptable salts thereof.

13. The compound according to Claim 12, wherein A is a cyclopentyl, cyclohexyl, cycloheptyl, dioxanyl, tetrahydrofuranyl, or oxanyl, ring fused to a phenyl, or pyrrolyl ring, optionally fused to a phenyl ring to form a tricyclic ring wherein the A ring system is optionally substituted with one, two or three R^b substituents;

and pharmaceutically acceptable salts thereof.

14. The compound according to Claim 8, wherein:

R^1 is selected from phenyl and 4-chlorophenyl;

R^2 is selected from:

(1) phenyl, and

(2) pyridyl,

wherein phenyl and pyridyl are optionally substituted with one or two halogen substituents;

R^3 is methyl;

R^4 is selected from hydrogen and methyl;

A is selected from:

(1) benzodioxanyl,
(2) indanyl,
(3) 1,2,3,4-tetrahydronaphthyl,
(4) 6,7,8,9-tetrahydro[a][7]annulenyl,
(5) chromanyl,
(6) 2,3-dihydrobenzyl furanyl,
(7) 1,2,3,4-tetrahydroquinolinyl,
(8) 1,2,3,4-tetrahydroisoquinolinyl,
(9) 1,2,3,4-tetrahydro-1,4-quinazolinyl, and
(10) 1,2,3,4-tetrahydrocarbolinyl,

each optionally substituted with one, two, or three groups independently selected from R^b;

each R^b is independently selected from:

(1) methoxy,
(2) halogen,
(3) -SH,
(4) $-SCH_3$,
(5) $-NH_2$,
(6) $-C(O)CH_3$,
(7) $-CO_2H$,
(8) $-CO_2CH_3$,
(9) $-CF_3$,
(10) $-OCF_3$,
(11) C_{3-6} cycloalkyl,
(12) C_{1-4}alkyl,
(13) phenyl,
(14) benzyl, and
(15) heteroaryl;

and pharmaceutically acceptable salts thereof.

15. The compound according to Claim 8, selected from:

(1) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide,

(2) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-indane-1-carboxamide,

(3) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2,3-dihydrobenzofuran-2-carboxamide,

(4) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydrocarbazole-1-carboxamide,

(5) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetrahydro-2-naphthamide,

(6) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydrobenzofuran-2-carboxamide,

(7) *N*-[2,3-bis(4-chlorophenyl)-1-methypropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide,

(8) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide,

(9) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide,

(10) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide,

(11) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide,

(12) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]chromane-2-carboxamide,

(13) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]chromane-2-carboxamide,

(14) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide,

(15) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methylchromane-2-carboxamide,

(16) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]chromane-3-carboxamide,

(17) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]chromane-3-carboxamide,

(18) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-3-methylchromane-3-carboxamide,

(19) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-3-methylchromane-3-carboxamide,

(20) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,

(21) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,

(22) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide,

(23) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide,

(24) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,

(25) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide,

(26) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide,

(27) *N*-[2,3-bis(4-chlorophenyl)-1-methypropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-7-carboxamide,

(28) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-7-carboxamide,

(29) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,

(30) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,

(31) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-3-methylchromane-3-carboxamide,

(32) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,

(33) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-6-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide,

(34) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-7-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide;

and pharmaceutically acceptable salts thereof.

16. The compound according to Claim 8, selected from:

(1) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide,

(2) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-indane-1-carboxamide,

(3) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2,3-dihydrobenzofuran-2-carboxamide,

(4) *N*-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydrocarbazole-1-carboxamide,

(5) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetrahydro-2-naphthamide, diastereomer I,

(6) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetrahydro-2-naphthamide, diastereomer II,

(7) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetrahydro-2-naphthamide, diastereomer III,

(8) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetrahydro-2-naphthamide, diastereomer IV,

(9) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydrobenzofuran-2-carboxamide diastereomer I,

(10) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydrobenzofuran-2-carboxamide diastereomer II,

(11) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydrobenzofuran-2-carboxamide, diastereomers I and II (1:1),

(12) *N*-[2,3-bis(4-chlorophenyl)-1-methypropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide diastereomer I,

(13) *N*-[2,3-bis(4-chlorophenyl)-1-methypropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide diastereomer II,

(14) *N*-[2,3-bis(4-chlorophenyl)-1-methypropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide, diastereomers I and II (1:1),

(15) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide diastereomer I,

(16) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide diastereomer II,

(17) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide, diastereomers I and II (1:1),

(18) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide diastereomer I,

(19) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide, diastereomer II,

(20) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide diastereomers I and II (1:1),

(21) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide diastereomer I,

(22) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide diastereomer II,

(23) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide diastereomers I and II (1:1),

(24) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]chromane-2-carboxamide diastereomers I and II (1:1),

(25) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]chromane-2-carboxamide diastereomers I and II (1:1),

(26) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide diastereomer I,

(27) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide diastereomer II,

(28) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide diastereomers I and II (1:1),

(29) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methylchromane-2-carboxamide diastereomer I,

(30) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methylchromane-2-carboxamide diastereomer II,

(31) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methylchromane-2-carboxamide diastereomers I and II (1:1),

(32) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]chromane-3-carboxamide diastereomers I and II (1:1),

(33) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]chromane-3-carboxamide diastereomers I and II (1:1),

(34) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-3-methylchromane-3-carboxamide diastereomers I and II (1:1),

(35) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-3-methylchromane-3-carboxamide diastereomers I and II (1:1),

(36) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,

(37) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

(38) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1),

(39) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,

(40) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

(41) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1),

(42) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide, diastereomer III,

(43) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer IV,

(44) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,

(45) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

(46) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1),

(47) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (3:1),

(48) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1),

(49) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

(50) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomer I,

(51) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomer II,

(52) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomers I and II (1:1),

(53) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomer I,

(54) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomer II,

(55) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diastereomers I and II (1:1),

(56) *N*-[2,3-bis(4-chlorophenyl)-1-methypropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-7-carboxamide diastereomers I and II (1:1),

(57) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-7-carboxamide diastereomers I and II (1:1),

(58) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I enantiomer A,

(59) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I enantiomer B,

(60) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I, enantiomer A,

(61) *N*-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I, enantiomer B,

(62) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-3-methylchromane-3-carboxamide diastereomer I,

(63) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-3-methylchromane-3-carboxamide diastereomer II,

(64) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,

(65) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

(66) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-6-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,

(67) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-7-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,

(68) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-6-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

(69) *N*-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-7-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,

and pharmaceutically acceptable salts thereof.

17. A method of treating a disease mediated by the Cannabinoid-1 receptor comprising administration to a patient in need of such treatment of a therapeutically effective amount of a compound according to Claim 1.

18. The method according to Claim 17 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

19. The method according to Claim 18 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

20. The method according to Claim 19 wherein the eating disorder asssociated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

21. The method according to Claim 20 wherein the eating disorder associated with excessive food intake is obesity.

22. A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.001 mg to about 100 mg per kg of a compound according to Claim 1.

23. A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

24. The use of a compound according to Claim 1, for the manufacture of a medicament useful for the treatment of a disease mediated by the Cannabinoid-1 receptor in a human patient in need of such treatment.

25. The use according to Claim 22 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease,

schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake.

26. The use according to Claim 25 wherein the disease mediated by the Cannabinoid-1 receptor is an eating disorder associated with excessive food intake.

27. The use according to Claim 26, wherein the eating disorder asssociated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.

28. The use according to Claim 27 wherein the eating disorder associated with excessive food intake is obesity.

29. The use of a compound according to Claim 1 for the manufacture of a medicament for the prevention of obesity in a person at risk therefor.